DR3 (TNFRSF25) Human shRNA Lentiviral Particle (Locus ID 8718)

CAT#: TL308731V

TNFRSF25 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL308731A virus into HEK293 cells. TL308731A virus was prepared using lenti-shRNA TL308731A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL308731B virus into HEK293 cells. TL308731B virus was prepared using lenti-shRNA TL308731B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL308731C virus into HEK293 cells. TL308731C virus was prepared using lenti-shRNA TL308731C and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL308731D virus into HEK293 cells. TL308731D virus was prepared using lenti-shRNA TL308731D and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 8718
• Synonyms: APO-3; DDR3; DR3; GEF720; LARD; PLEKHG5; TNFRSF12; TR3; TRAMP; WSL-1; WSL-LR
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001039664, NM_003790, NM_148965, NM_148966, NM_148967, NM_148968, NM_148969, NM_148970, NM_148971, NM_148972, NM_148973, NM_148974, BC117189, BC143886, BM666370
• Summary: The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed preferentially in the tissues enriched in lymphocytes, and it may play a role in regulating lymphocyte homeostasis. This receptor has been shown to stimulate NF-kappa B activity and regulate cell apoptosis. The signal transduction of this receptor is mediated by various death domain containing adaptor proteins. Knockout studies in mice suggested the role of this gene in the removal of self-reactive T cells in the thymus. Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported, most of which are potentially secreted molecules. The alternative splicing of this gene in B and T cells encounters a programmed change upon T-cell activation, which predominantly produces full-length, membrane bound isoforms, and is thought to be involved in controlling lymphocyte proliferation induced by T-cell activation. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).